Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.38 |
| ▸ | STK10 | O94804 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL34433935 | 0.99 | MRGPRX4 (0.42) | MRGPRX4ARGPR119LRRK2SLK | |
| SCHEMBL23235773 | 0.88 | MRGPRX4 (0.51) | MRGPRX4ARLRRK2SLKSTK10 | |
| Hydrochloric Acid SCHEMBL23235835 | 0.87 | MRGPRX4 (0.50) | MRGPRX4ARSLKSTK10 | |
| SCHEMBL23541002 | 0.85 | MRGPRX4 (0.44) | MRGPRX4ARGPR119SLKSTK10 | |
| SCHEMBL29741540 | 0.84 | AR (0.45) | MRGPRX4ARXDH | |
| SCHEMBL23566024 | 0.84 | AR (0.45) | MRGPRX4ARXDH | |
| Hydrochloric Acid SCHEMBL29741557 | 0.83 | AR (0.44) | MRGPRX4ARXDH | |
| SCHEMBL23235861 | 0.80 | MAOB (0.56) | ARKIF11 | |
| SCHEMBL1060980 | 0.79 | MAOB (0.58) | MRGPRX4SLKSTK10 | |
| SCHEMBL27112675 | 0.77 | AR (0.48) | ARPTGDR2XDHNR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| CN-119837855-A | Compounds for the treatment of bacterial infections and for the enhancement of antibiotics | 乔治亚州大学研究基金会 | 2025-04-18 | — | — | CN | disclosed |
| EP-4076420-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | Georgia State University Research Foundation, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114845708-A | Compounds for treating bacterial infections and enhancing antibiotics | 乔治亚州大学研究基金会 | 2022-08-02 | — | — | CN | disclosed |
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2021127452-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | MRGPRX4 546/4885AR 4411/4885GPR119 3774/4885 |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | CLIC1, CBR3, CBR1 | MRGPRX4 1974/4885AR 3082/4885GPR119 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.